DRUG/DEVICE

Treprostinil inhalation powder

ROUTE OF ADMINISTRATION

Inhaled

THERAPEUTIC PLATFORM

Tyvaso®

CLINICAL TRIAL

TERRITORY

Worldwide

COMMERCIAL PRODUCT

www.tyvaso.com

STATUS

Phase 3 BREEZE and pivotal pharmacokinetic studies completed; NDA planned for first half of 2021

Tyvaso DPI is an investigational combination product that is not approved for any use in any country, and the Tyvaso DPI tradename is pending FDA review.